Pharmacy Website
Clinic Website

Intelligence » Psoriasis » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

J&J; says its psoriasis drug superior to Novartis' in study

Wednesday, December 12, 2018 -- Johnson & Johnson said its drug Tremfya was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.

Guselkumab Compared With Secukinumab in Head-to-Head Plaque Psoriasis Trial

Wednesday, December 12, 2018 -- In the ECLIPSE study (N=1048), patients were randomized to receive guselkumab 100mg at weeks 0, 4, and 12 followed by every 8-week dosing or secukinumab 300mg at weeks 0, 1, 2 3, 4 followed by every 4-week dosing.

Tremfya Tops Cosentyx in Head-to-Head Psoriasis Trial

Thursday, December 13, 2018 -- (MedPage Today) -- More patients almost clear of plaque at week 48

Ustekinumab May Benefit Subclinical Enthesopathy in Patients With Psoriasis

Monday, December 17, 2018 -- Researchers investigated whether sonographically determined subclinical enthesopathy in patients with moderate to severe psoriasis regressed under therapy with ustekinumab.